Results From Chelsea Therapeutics, Inc. (CHTP)' Pivotal Northera(TM) (Droxidopa) Study to be Presented at the American Academy of Neurology's Annual Meeting
4/27/2012 9:24:04 AM
CHARLOTTE, N.C., April 27, 2012 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) today announced that Horacio Kaufmann, M.D., Professor of Medicine, NYU Langone Medical Center, New York, will present the full results from the previously reported Northera™ (droxidopa) Study 301 during the oral Clinical Trials Forum at the American Academy of Neurology 64th Annual Meeting in New Orleans, Louisiana, at 12:15 PM ET today. Overall, the results of the study showed droxidopa demonstrated statistical improvement compared to placebo in the trial for the primary clinical endpoint (OHQ composite score), which provides a comprehensive measure of symptoms for neurogenic orthostatic hypotension (known as Neurogenic OH or NOH). The results were consistent irrespective of gender, concomitant medications or primary diagnosis.